CONCLUSION: Based on the data obtained in this study, widely-implemented prophylactic HPV vaccination could make an important contribution to the reduction of the risk for cervical cancer and could also prevent about half the vulvar carcinomas in younger women and about two thirds of the intraepithelial lesions in the lower genital tract.
CONCLUSION:
Based on the data obtained in this study, widely-implemented prophylactic HPV vaccination could make an important contribution to the reduction of the risk for cervical cancer and could also prevent about half the vulvar carcinomas in younger women and about two thirds of the intraepithelial lesions in the lower genital tract. (Obstet Gynecol 2006; 108:1361-8) 
LEVEL OF EVIDENCE: II-3
V ulvar cancer is the fourth most common gynecologic cancer, with an incidence of 1.5-2 per 100,000 women per year in Germany; it is six times less frequent than cervical cancer (12 per 100,000 women per year). In Germany, 559 women died from vulvar cancer in 1999. In the United States it was estimated that there would be 3,740 new cases and 880 deaths in 2005. 1 Cigarette smoking, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), persistent human papillomavirus (HPV) infection, immunodeficiency syndromes, previous history of cervical intraepithelial neoplasia or cervix cancer, and northern European ancestry have been identified as risk factors for the development of vulvar cancer. Vulvar intraepithelial neoplasia are precursor lesions for invasive squamous cell carcinoma of the vulva and their incidence is currently estimated to be 2.1 per 100,000 women per year.
There has been a striking increase in the incidence of VIN and vulvar carcinoma over the past 30 years, especially in younger women. [2] [3] [4] [5] [6] [7] The observed increase in younger women could be due to a higher incidence of infection of the lower genital tract with human papillomavirus or it may be explained by better diagnostic procedures or both.
Vulvar carcinoma can be HPV-positive or HPVnegative. 8, 9 Human papillomavirus-positive tumors tend to be nonkeratinizing basaloid or warty tumors, often surrounded by bowenoid-type vulvar intraepithelial neoplasia. 10 -12 Human papillomavirus 16 is the most frequently observed virus in these tumors. 2, 10, 11, [13] [14] [15] [16] Human papillomavirus-positive tumors, which are associated with younger patients, have been diagnosed more frequently in recent decades and are thought to have a better prognosis than the HPV-negative tumors. 2, 5, 7, 11, [17] [18] [19] [20] Human papillomavirus-negative tumors are more frequently found in older women, often with a history of nonneoplastic epithelial disorders of the vulvar skin, such as lichen sclerosis. 10, 11, 21 These are differentiated keratinizing squamous cell carcinoma and the corresponding precursor lesions are called "simplex" or well-differentiated VIN. 9, 11, 21 These latter tumors are usually unifocal, more aggressive, and they tend to recur and metastasize earlier. 18, 20 At least 70% of women are infected with HPV during their lifetime, and this virus is responsible for the most common sexually transmitted infections worldwide. However, most HPV infections are asymptomatic and clear spontaneously within 12-18 months. Less then 10% of women have persistent infection but this is a risk factor for the development of lower genital tract intraepithelial dysplasia, predominantly located at the cervix (cervical intraepithelial neoplasia: CIN). When untreated, these precursor lesions can progress to invasive cervical cancer in a gradual process that might take between 10 and 12 years from primary infection to the development of invasive cancer. 22 The results from epidemiologic studies of cervical cancer specimens show that 99.7% of these tumors are HPV-positive, with HPV 16 and 18 being responsible for approximately 70% of the tumors. 23 Two prophylactic vaccines have been developed to prevent infections with these high-risk HPV types, aiming to reduce the worldwide incidence of these tumors. 24 -26 Initial trials have shown highly efficient protection against infections with HPV 16 and 18. In addition, one of the two vaccines is directed against two low-risk HPV types, 6 and 11, that The study protocol was approved by the institutional review boards at both sites. All patients underwent surgical treatment consisting of either CO 2 laser vaporization after biopsy, CO 2 laser excision or knife excision for vulvar, vaginal, or anal intraepithelial neoplasia. Vulvar squamous cell carcinomas were treated by wide local excision or vulvectomy, including complete inguinofemoral lymphadenectomy. Before surgery, all women gave their signed informed consent to inclusion in this study. In the majority of women, a colposcopy-guided biopsy was performed before surgical treatment to confirm the diagnosis. Only surgical specimens of histologically confirmed intraepithelial neoplasia of the vagina, vulva, or anal region or vulvar carcinoma were included in the study. The specimens were examined by an experienced gynecologic pathologist and the diagnosis was based on published histomorphologic criteria. 27 For each patient the location and number of lesions, their age at diagnosis, smoking habits, prior history of HPV induced diseases (ie, cervical HPV-induced disease, condyloma, multicentric HPV-induced lesions) and their human immunodeficiency virus (HIV) status were recorded.
MATERIALS AND METHODS
All histologic and molecular tests were performed under blind conditions. Single-use scalpels were used to prevent carry-over contamination in the subsequent DNA extraction and polymerase chain reaction (PCR) amplification. The histologic diagnosis was made on serial sections of formalin-fixed paraffin-embedded tissue samples. Serial sections (5 mcm) of intraepithelial neoplastic lesions or invasive vulvar cancer from the paraffin blocks containing the most disease-specific changes were selected for HPV DNA analysis by PCR and sequencing. After deparaffinization, genomic DNA was extracted using the QIAamp DNA Mini Kit (QIA-GEN, Hilden, Germany) according to the manufacturer's instructions. The quality of the extracted DNA was evaluated by spectrophotometry (Beckman Coulter, Krefeld, Germany).
Human papillomavirus DNA was detected using a two-tier PCR-direct sequencing method, modified as indicated below. 28, 29 We used the general primers GP5ϩ/GP6ϩ 30 and the consensus primer pair MY09 and MY11 for amplification of the corresponding part of the HPV L1 gene, with different fluorescent labeling of each of the forward primers. A 20-mcL standard PCR (3 mcL DNA, 2 mcL 10ϫPCR buffer, 0.2 mM dNTPs, 20 pmol primer each, MgCl 2 1.5 mM, 1 Unit Taq polymerase) was run with 40 cycles of denaturation at 94°C for 20 seconds, and annealing for 20 seconds at 39°C for the general primers and at 55°C for the MY09, MY11, and ␤-globin primers, followed by an extension at 72°C for 40 seconds. The initial denaturation was performed at 94°C for 5 minutes, and the final extension was performed at 72°C for 5 minutes. The integrity of human genomic DNA was verified by PCR amplification of a 268 base-pair fragment of the ␤-globin gene. The DNA extracted from HPV 16-positive Caski cells was used as a positive control, and for the negative control, water was used as template instead of DNA. The lower limit of the number of viral copies to result in a positive test was estimated to be 300 -400 copies of HPV depending on the type.
An aliquot (0.8 mcL) of each of the three PCR products was mixed with 10 mcL formamide and 0.5 L internal standard (GENESCAN 500-ROX; Applied Biosystems, Foster City, CA). After denaturation at 90°C for 2 minutes and cooling, the PCR products were analyzed on an automated ABI 310 genetic analyzer (Applied Biosystems). The PCR product sizes were determined using GENESCAN 2.1.1 software (Applied Biosystems). We controlled for inter-and intra-assay variation by monitoring the fluorescence in the positive controls in each run and by duplicate testing of randomly selected samples in one run.
Positive PCR products were purified using the High Pure PCR product purification kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. The sequence of one strand of the purified PCR fragments was determined with the Big-Dye Terminator sequencing kit (Applied Biosystems) using 3-5 pMol of GP6ϩ or MY09 as sequencing primers, and analyzed on an ABI Prism 310 automated sequencer (Applied Biosystems). These sequences were compared with the documented virus sequences available in the GenBank databank using the BLAST Program (Blast, Pittsboro, NC). When multiple fluorescent peak patterns were observed in the GENESCAN analyzes, type-specific PCR for the seven most common HPV types 6, 11, 16, 18, 31, 33 and 51 was performed.
31 Stratified analyses were performed by age, histology, and center, and a twosample Wilcoxon rank sum test, Pearson 2 test, or t test, were applied, where applicable, to test for significant differences. Furthermore, univariable and multivariable data analyses were conducted using logistic regression, to examine factors independently associated with HPV status (ie, positive or negative for HPV). All data analyses were conducted using STATA 8.2 (StataCorp, College Station, TX). P values presented are two-tailed and the results were considered statistically significant at PՅ.05).
RESULTS
During our study revised guidelines for VIN terminology from the International Society for the Study of Vulvovaginal Disease were published. Before this, squamous vulvar intraepithelial neoplasia were classified as either low-grade lesions (VIN 1), mediumgrade lesions (VIN 2), or high-grade lesions, including carcinoma in situ (VIN 3) In the new guidelines, the term VIN 1 was no longer recommended for use, and the term "VIN" now encompasses the former VIN 2 and VIN 3 lesions. We, therefore, eliminated the samples that were classified as VIN 1 (nϭ14), corresponding to 13 women. 32 We combined the samples classified as VIN 2 and VIN 3 from 168 women into a single diagnostic category termed VIN2/3 (nϭ183). We also combined the VaIN 2 and VaIN 3 samples from 11 women into one category termed VaIN2/3 (nϭ11), and the AIN2/3 samples from 14 women were analyzed separately (nϭ16). Thus, 210 samples of histologically confirmed nondifferentiated intraepithelial neoplastic lesions of the lower genital tract from 193 women (17 women had two lesions) and 48 specimens of microinvasive and invasive vulva carcinoma from 48 women were included in the analysis.
Multifocal disease was observed in 27% (70 of 258) of the samples. Of the 48 samples of invasive vulva carcinoma, 11 were diagnosed as microinvasive carcinoma (depth of infiltration less than 1 mm) arising from VIN 3. Only two patients were seropositive for HIV, and none of the other women had any immunodeficiency conditions. The two HIV-infected patients were aged 21 
The mean age of the patients is listed in Table 1 , as well as the number of HPV positive samples (92%, 91%, 88%, and 60% of the VIN2/3, VaIN2/3, AIN2/3, and vulvar carcinoma samples, respectively). Women with VIN2/3 and vulvar carcinoma HPVpositive samples were significantly younger than those with HPV-negative samples (PϽ.05; Table 1 ). This was observed in both treatment centers. As expected, HPV-positive vulvar carcinoma was more frequent in women aged younger than 56 years (77%), than in those aged 56 years or older (41%); adjusting for center, this difference was statistically significant (odds ratio [OR] 4.3, 95% confidence interval [CI] 1.2-15.4) ( Table 2 ). However, we identified a HPVpositive vulva carcinoma (HPV 6, 31, and 68) in an 83-year-old woman and a HPV-negative microcarcinoma with 1.2-mm infiltration and without surrounding lichen sclerosus in a 32-year-old woman.
Females in center 2 with a VIN2/3 were, independent of age, more likely to have HPV-positive samples compared with center 1 (Pϭ.03). This difference in HPV positivity between centers was not seen in women with vulvar carcinoma, VaIN2/3, or AIN2/3. Testing for effect modification between HPV positivity, age, and center did not show any significant differences.
The majority of the HPV-positive samples (91%, 90%, 71% ,and 83%, for the VIN2/3, VaIN2/3, AIN, and vulvar carcinoma samples, respectively) contained only high-risk HPV types (single or multiple infections: Table 3 ). Low-risk HPV types only were observed in less than 5% of the samples. Infections with two or more different HPV types were present in 13%, 10%, 21%, and 13% of the VIN2/3, VaIN2/3, AIN, and vulvar carcinoma samples, respectively.
The distribution of HPV types is summarized in Table 3 . High-risk HPV types 16 or 18 were found in VIN2/3, vulvar intraepithelial neoplasia; VaIN2/3, vaginal intraepithelial neoplasia; AIN2/3, anal intraepithelial neoplasia; HPV, human papillomavirus. Data are n, n (Ϯstandard deviation), or n (%). * Multicentric HPV-induced disease includes history of or concordant condyloma, cervical, vaginal or anal intraepithelial neoplasia. Human papillomavirus 16 and 18 were detected in 76% of the VIN2/3 lesions (139 of the 183 lesions analyzed); therefore, if the prophylactic HPV vaccine were to be implemented, we could expect that three in four VIN2/3 lesions would be prevented, because the vaccine has been shown to prevent 100% of infections by HPV 16 and 18. In addition, HPV 16 and 18 were detected in 58% (15/26) of the vulvar carcinoma samples in the subgroup of younger women (younger than 56 years); and therefore, widespread vaccination could prevent more than one half of the vulvar carcinomas in these women.
DISCUSSION
Here we report the results from a large case series from Dü sseldorf, Germany in which sensitive HPV DNA-detection techniques (PCR and DNA sequencing) were used. In this case series of 258 samples of intraepithelial neoplasia of the vagina, vulva, and anus and invasive carcinoma from 241 women, the median age was 48 years, which is young, but provides further evidence of the increasing frequency of these lesions in younger women in recent years. 6, 33 A literature search performed in PubMed (http:// www.ncbi.nlm.nih.gov) using the search terms vulvar carcinoma, HPV, and pathogenesis from 1970 to May 2006 with no language restrictions showed that presence of HPV DNA in VIN and vulvar cancerous lesions has been reported to vary from 0% to 89%. 2,8 -17,20,34 -47 The published studies have generally involved relatively few samples and the methods used for HPV DNA detection have had different sensitivities. This wide variation is probably due to the small sample sizes, differences in patients recruited and HPV detection methods used, and the year of publication.
In our study, HPV DNA was detected in 86% of all samples (Table 1) , which seems to be high compared with the percentages reported in other studies. However, many of these previous studies were conducted more than 10 years ago. In addition, our results, which show that 60% of the vulvar carcinomas and 92% of the VIN2/3, VaIN2/3, and AIN samples were HPV-positive (Table 1) , are similar to results from the most recent studies, which reported 60 -85% HPV-positive vulvar carcinomas 2, 20 and 71-80% HPV-positive high-grade VIN. 39, 48 Many epidemiologic studies assessing the presence of HPV in lower genital tract carcinomas have focused on cervical carcinoma. Their results show that HPV DNA can be detected in more than 99% of the lesions, thus establishing the role of HPV infection as a necessary cause of these carcinomas. 23, 49 In contrast, until recently, few studies have examined the role of HPV infection in vulvar carcinoma. 2,8 -17,20,33,34,36 -44 The number of HPV-positive invasive vulvar carcinoma in younger woman has increased in the last decade from about 2-5% to more than 20% of all cases of invasive vulvar carcinoma. 2, 5, 7, 19 We observed a similar trend toward younger age in our cohort of patients with invasive vulvar carcinoma. The increase in the incidence of VIN with microinvasion, and of invasive carcinoma in younger woman seems to be associated with the increased incidence of HPV infection of the lower genital tract.
In the majority of women with basaloid and warty type of vulvar cancer (more frequent among younger women), 11, 50 HPV 16, 18, 31 , and 33 are the most frequent HPV types detected, whereas HPV 45, 6, and 11 are rarely detected. 2, 7, [13] [14] [15] [16] 20, 35, 39, 44, 51 Our data are consistent with these findings, with HPV 16 being, by far, the most common type (76% of the HPVpositive samples) followed by HPV 33 (10%).
This analysis has been performed on one of the largest series of samples, using PCR techniques that are very sensitive for detecting HPV. However, in our study, the samples were paraffin-embedded, and therefore the PCR technique is not as sensitive as with non-paraffin-embedded samples. We estimate that the sensitivity is between 100 and 300 viruses, depending on the HPV type, compared with sensitivity reported in the original publication of the method, which was 10 viruses. Therefore, our analysis may underestimate the presence of HPV in our samples. Despite this limitation, our results confirm those obtained in the previously reported studies. 2,8 -17,20,33-46 Prophylactic HPV vaccines have been reported to be highly immunogenic and well-tolerated with no severe adverse events. 24, 26, 52 Results from phase III studies with the quadrivalent prophylactic vaccine in more than 25,000 young persons, including 1,000 adolescent boys and girls, show a high seroconversion rate of up to 98%, with a persistent antibody titer for at least 5 years. The efficacy for preventing HPV 6-, 11-, 16-and 18-related genital warts, VIN, and vaginal or vulvar carcinoma after 2 years follow-up in 2,261 vaccine and 2,279 placebo recipients was 100% (95% CI 88 -100%): 40 histologically confirmed events in the placebo group and none in the vaccine group (Villa et al. Oral presentation at EUROGIN 2006, Paris, France, April 24 -26, 2006 ). Thus, a prophylactic vaccine for HPV 16 and 18 might be effective in reducing the incidence of highgrade VIN, VaIN, and AIN, because HPV 16 and 18 were detected in 76% of the VIN2/3, VaIN2/3, and AIN2/3 lesions (159 of a total of 210 lesions analyzed). In addition, although HPV 16 and 18 were detected in 42% of the vulvar carcinoma samples, independent of the patient's age (20 of 48 samples analyzed), in the subgroup of younger women (younger than 56 years; nϭ26), HPV 16 and 18 were detected in 58% (15/26) of the samples.
Although the incidence of vulvar cancer has increased over the past 30 years 4, 6 and is still increasing (in the United States it is estimated to be increasing at a rate of 1.2% per year 1 ) vulvar lesions remain less frequent than cervical lesions. Although the results from a recent systematic review suggest that although some VIN lesions do progress to invasive vulvar carcinoma, the progression rate is low. 53 However, the treatment of vulvar lesions is often mutilating and traumatic for women, and the high-grade lesions have an elevated risk of recurrence. Therefore, prevention of these lesions would reduce the number of multiple treatment sessions, mutilating operations, and trauma in women with these lesions. Prophylactic HPV vaccination might have a large effect on the control of HPV-associated human cancers, and could make a significant contribution to the reduction of the risk for cervical as well as that for vulvar cancers in women. We conclude that if prophylactic HPV vaccination is widely implemented, approximately one half of the vulvar carcinomas in younger women (younger than 56 years) (current incidence: approximately 1 per 100,000 women per year), and approximately two thirds of the intraepithelial precursor lesions in the lower genital tract (current incidence: 2.1 per 100,000 women per year) might be prevented.
